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Cover letter 22 
 23 
Dear Editor-in-Chief, 24 
Please receive our article titled “Paget’s disease of bone biphosphonates and jaw  25 
osteonecrosis: a case report” for open evaluation in Nemesis journal.  26 
1) Summarize the study’s contribution to the scientific literature: Bisphosphonates  27 
have been the treatment of choice of Paget’s disease since the 1990s. Medication  28 
related osteonecrosis of the jaw (MRONJ) is a rare event in non oncologic  29 
patients. We describe a rare case of Paget’s disease involving the maxilla with  30 
osteonecrosis in a context of bisphosphonate treatment. 31 
2) Relate the study to previously published work: Maxillofacial involvement of  32 
Paget’s disease occurs in less than 15% of cases. There is a lack of information in  33 
the literature about the association of MRONJ and Paget’s disease. 34 
3) Specify the type of article (for example, research article, systematic review,  35 
meta-analysis, clinical trial): we provide with a case report. 36 
4) Describe any prior interactions with Nemesis regarding the submitted  37 
manuscript: we have no prior interactions with Nemesis journal.  38 
5) Nemesis aim and scope relevance: side effect of bisphosphonate treatment 39 
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Abstract  59 
Objective: Paget’s disease of bone is characterized by a focal increase in bone  60 
resorption and accelerated bone formation leading to a weaker and disorganised 61 
bone. Bisphosphonates (BPs) have been the treatment of choice of Paget’s disease 62 
since the 1990s. Medication related osteonecrosis of the jaw (MRONJ) is a rare 63 
event in non oncologic patients. We describe a rare case of  Paget’s disease  64 
involving the maxilla with osteonecrosis in a context of bisphosphonate treatment. 65 
 66 
Case report: an 87-year-old woman presented with 4 episodes of bone necrosis 67 
in 15 years. In this case report there is a clear chronologic association between the 68 
occurrence of MRONJ and the administration of iv BP for Paget’s disease. 69 
Maxillofacial involvement of Paget’s disease occurs in less than 15% of cases. 70 
There is a lack of information in the literature about the association of MRONJ and 71 
Paget’s disease. Even if osteonecrosis of the jaw could be a consequence of the  72 
disease, in this case, it is more in relation to the BP treatment. 73 
 74 
Conclusions: Although MRONJ might be considered a rare condition in Paget’s 75 
disease, patients prior to starting antiresorptive therapy and in particular iv BPs 76 
should have a complete dental examination and panoramic X-Ray.  77 
 78 
Nemesis relevance: side effect of bisphosphonate treatment 79 
 80 
Keywords Paget’s disease, jaw osteonecrosis, bisphosphonates 81 
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Introduction  95 
Paget’s disease of bone (PD) is characterized by a focal increase in bone resorption 96 
and accelerated bone formation leading to a weaker and disorganised bone. It can  97 
affect one or more site throughout the skeleton [1]. 98 
Described in 1876 by Sir James Paget, this “osteitis deformans” is the second most 99 
common metabolic bone disease after osteoporosis.  100 
The disease affects preferentially a male population after 55 y. The incidence is 101 
higher in Western Europe, Australia and in America, affecting 2-7% of the  102 
Caucasian population [2, 3]. 103 
The maxillofacial type occurs in less than 15% of patients, and the maxilla is more 104 
commonly affected than the mandible by a 2:1 ratio [4].  105 
Treatment of PD tends to relieve bone pain and restore normal turnover.  106 
Bisphosphonates (BPs) have been the treatment of choice since the 1990s, either in 107 
the form of oral BPs (alendronate, risedronate…) or IV BPs (pamidronate, 108 
zoledronate). The frequency and dose of BPs treatment is determined by patient  109 
response [1].  110 
Medication related osteonecrosis of jaws (MRONJ) was first described in 2003  111 
under the name of bisphosphonate related osteonecrosis of the jaw [5, 6]. The vast 112 
majority of cases occur in patients with advanced malignancies and skeletal  113 
metastases who have received frequent, high cumulative doses of antiresorptive 114 
therapy (IV BPs or denosumab). Less than 5% of MRONJ occurs in non-cancer  115 
patients (osteoporosis, Paget’s disease, fibrous dysplasia, rheumatoid arthritis…), 116 
which received lower and less frequent doses of oral, iv BPs or denosumab and  117 
presented with less comorbidity [3,7].  118 
We report a case of Paget’s disease of the skull and maxilla in a patient who  119 
received multiple courses of IV BPs and presented with 4 episodes of maxillary 120 
bone necrosis.  121 
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Case report 135 
An 87-year-old non-smoking Caucasian woman was referred to the outpatient 136 
maxillofacial department in 2009 for maxillary bone pain that had evolved over the 137 
previous 3 months. She was diagnosed with Paget’s disease affecting the skull and 138 
maxilla in 1965 (Figure 1).  139 
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Fig. 1 Plain X-Ray demonstrating typical cotton wool aspect and bone 160 
enlargement in the maxillary and cranial vault. 161 
 162 
No other comorbidity was ascertained. The patient received 11 infusions of  163 
pamidronate (30 to 60 mg) from 1993 to 1995, with the last infusion occurring one 164 
month before she underwent maxillary surgical extractions and decortication to treat 165 
chronic infection and maxillary enlargement. At that time BPs were administrated to 166 
reduce the vascularity of bone to prevent excessive PD-related bleeding. Following 167 
these surgical extractions, the sockets failed to heal and bone exposure persisted  168 
despite numerous interventions. Two years after the extraction, there was still an  169 
area of bone exposure in the posterior left maxillary and a large sequestrum in the 170 
anterior right maxillary. After right sequestrectomy in 1997, she developed a right 171 
oroantral fistula. The left maxillary region was debrided and mucosa was closed. A 172 
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maxillary obturator prosthesis was adjusted a few months later. BPs treatment was 173 
stopped for 5 years because the patient had not any symptoms from Paget’s disease. 174 
During these five years, the patient was still free of intra-oral problems and bone  175 
exposure. Between 2002 and 2009, she received 6 courses of pamidronate (180 mg 176 
in 3 days) and 7 courses of IV alendronate (20 mg in 2 days) for ocular problems 177 
(compression). In 2002, she sought treatment for left maxillary infection, probably 178 
due to compression of a poorly fitted prosthesis, which was complicated by bone 179 
exposure and a left maxillary sequestrum. She was treated with local debridement, 180 
sequestrectomy and wound closure. A larger oroantral fistula then developed on the 181 
treated left side. Her obturator prosthesis was adapted. In January 2009, one month 182 
after her last injection of alendronate, she presented with pain in the nasal spine  183 
region. On oral examination, bone exposure was detected in the left maxillary. A 184 
panoramic X-Ray (Figure 2), axial CT scan (Figure 3), coronal CT scan (Figure 4) 185 
and 3D CT scan (Figure 5) confirmed the presence of a left maxillary sequestrum. 186 
Spontaneous expulsion of the sequestrum (2x1 cm) 10 weeks after the symptoms 187 
began revealed a normal underlying mucosa (Figure 6). Pathological examination 188 
found necrotic lamellar bone and bacteria colonies. The patient’s serum alkaline 189 
phosphatase level, calcium and phosphate were within normal limits at that time. A 190 
new obturator prosthesis was made. The patient received a final course of IV  191 
alendronate in July 2009 and presented with a new episode of bone exposure and  192 
infection in March 2010 for which she received multiple course of antibiotics until 193 
resolution.  194 
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 220 
Fig. 2 Panoramic X-Ray, showing the same sequestrum and periostal 221 
reaction in the remaining maxillary bone. We can see the typical 222 
condensation of maxillary pagetic bone. Mandibular aspect seems to be 223 
normal. 224 
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 231 
 232 
Fig. 3 CT scan demonstrating the left maxillary sequestrum in an axial view. 233 
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Fig. 4 CT scan demonstrating the left maxillary sequestrum in a coronal view 242 
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Fig. 5 3D maxillofacial CT scan showing sequestration in the left maxila. 261 
Enlargement of the maxillary is typical of Paget’s disease. 262 
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Fig. 6 Spontaneous expulsion of a bone sequester 2x1 cm 278 
Discussion  279 
Paget’s disease (PD) of bone affects predominantly the skull, spine, hip, tibia and 280 
pelvis and can affect one or more site [1, 5]. Maxillofacial involvement occurs in 281 
less than 15% of patients and maxilla is more commonly affected than mandible  282 
(ratio 2:1) [4]. 283 
Only 5% of patients with PD will develop symptoms including pain, skeletal  284 
deformity, fractures, compression according to the involved site, dental  285 
complications and rare sarcomatous degeneration (< 1%). When PD affects the jaw, 286 
the most common problems are associated with dental extraction due to  287 
hypercementosis and ankylosis, leading to surgical extractions. Complications are 288 
excessive bleeding in the vascular lytic phase and delayed healing and infection in 289 
the avascular phase [3]. Following extraction persistent sinuses may develop. Other 290 
dental complications  291 
include enlargement of the bone, migration of the teeth, malocclusion, loss of teeth, 292 
and osteomyelitis. Jaw bone sequestration is very uncommon, and is more often 293 
mentioned as a complication of BPs treatment than as a feature of PD of the maxilla 294 
[8].  295 
Measurements of biological bone metabolism comprise parameters of bone  296 
formation such as serum alkaline phosphatase, C-terminal propeptide of type I  297 
collagen, N-terminal propeptide of type I collagen as well as parameters of bone  298 
resorption such as serum or urinary C-terminal telopeptide (CTX) and N-terminal  299 
telopeptide (NTX) of type I collagen [2]. 300 
Monostotic PD of bone usually does not provoke significant elevation of serum  301 
alkaline phosphatase. 302 
Aetiology of PD is unclear but genetic and viral components are suggested.  303 
Mutations in the sequestome SQSTM1/p62 gene were identified in 46% of familial 304 
Paget cases and 16% of patients with sporadic PD. The presence of virus-like  305 
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inclusions in the osteoclast nuclei, like paramyxovirus or syncitial respiratory virus 306 
has led to a viral hypothesis [1-3]. 307 
PD is considered to be a primary disorder of the osteoclast. The pathology is  308 
characterized by increased osteoclast bone resorption, followed by inadequate bone 309 
formation, leading to a disorganized bone with reduced mechanical strength [1].  310 
Symptomatic PD is the main indication for treatment (pain, nerve compression…) 311 
[1]. 312 
Treatment aims at the suppression of osteoclast activity and is achieved with 313 
bisphosphonates. 314 
The optimal regimen of BPs remains controversial. Oral formulations may be  315 
limited by complicated dosing regimens and poor gastrointestinal absorption.  316 
Currently, zoledronic acid is administrated as a single 5 mg infusion and normalizes 317 
alkaline phosphatase in the majority of patients [9, 10]. Denosumab had been used 318 
less frequently in patients refractory or intolerant to BPs [11].  319 
Medication related osteonecrosis of the jaw is defined as an exposed bone or bone 320 
that can be probed through an intraoral or extraoral fistula in the maxillofacial  321 
region that has persisted for longer than 8 weeks in a patient with current or previous 322 
treatment with antiresorptive 323 
or antiangiogenic agents, in the absence of radiation therapy to the jaws or obvious 324 
metastatic disease to the jaws [12]. 325 
The exact mechanism of MRONJ remains unclear. Alteration of bone turnover,  326 
hypovascularisation and infection seem to play a role. The majority of MRONJ are 327 
in relation with tooth extraction. 328 
The real incidence of MRONJ is still unknown and varies between 1,2% and 12,8% 329 
in cancer patients. In a report of Mavrokokki [13], the overall incidence of MRONJ 330 
is 1 in 930 with 1 in 87 for cancer patient, 1 in 2260 for osteoporotic patients and 1 331 
in 56 for Paget’s disease. For other authors the overall maximum frequency of  332 
extraction-related MRONJ is 1 in 125, with 1 in 11 for bone metastasis, 1 in 296 for 333 
osteoporosis, and 1 in 7,4 for PD [14, 15]. 334 
Limited data are available about the risk of MRONJ in patients affected by non  335 
neoplastic diseases. 336 
 337 
Only a few cases of MRONJ in PD patients have been reported in the literature. In a 338 
review in 2010, Filleul et al [16] analysed 2408 patients with MRONJ including 339 
0,7% of patients with PD. 340 
More recently, a systematic review from McGowan et al [17] identified 4106  341 
patients with MRONJ. Twenty-four patients presented with non malignant  342 
systematic diseases other than osteoporosis (0,5%) including 5 PD. 343 
 344 
Even sequestration can be an exceptional but normal complication in PD, treatment 345 
with BPs may be the trigger factor of the osteonecrosis. In our patient, the first  346 
episode of bone necrosis appeared after oral surgery and repeated doses of iv BP. 347 
The 3 following episodes of bone exposure occurred each time after close BPs 348 
courses. The diagnosis of MRONJ was thus retained. We have no information about 349 
Paget’s disease location in the literature reports. In our case report, maxillofacial  350 
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location is probably a worsening factor because of accumulation of BPs at sites of 351 
active bone remodelling thus in the pagetic maxilla.   352 
 353 
Although MRONJ might be considered a rare condition in Paget’s disease, patients 354 
prior to starting antiresoptive therapy and in particular iv BPs should have a  355 
complete dental examination and panoramic X-Ray. If therapy can be delayed, oral 356 
infection should be treated, restorative care, dental extraction for non salvage teeth 357 
should be carried on. Use of soft liners on denture also seems prudent. Once BPs 358 
treatment is started, regular oral examination and preventive approach are important 359 
for early diagnosis and treatment if necessary. Patients should be informed about the 360 
risk of developing MRONJ in association with oral surgery and invasive dental  361 
procedures, even if dental implant placement. The poor quality of bone in PD  362 
renders it susceptible to infection. In these at risk patients, the only “intervention” 363 
with a proven decreased risk of MRONJ is prevention, as it is the case with  364 
radiotherapy. 365 
This is the first description of a patient diagnosed with a maxillary localisation of 366 
Paget’s disease of bone presenting 4 episodes of MRONJ in 15 years, each bone  367 
exposure following a course of iv BPs. 368 
 369 
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